Latest news with #LifeSciCapital
Yahoo
06-07-2025
- Business
- Yahoo
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 26, Sam Slutsky, an analyst from LifeSci Capital, maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the associated price target at $50. He based the rating on the notable market opportunity for the company's IMVT-1402 for the treatment of Graves' disease, which is a leading cause of hyperthyroidism and has considerable unmet medical need. A closeup of a scientist working with a microscope in a biotech laboratory. The disease impacts around a million patients in the US, and current treatments typically render a majority of patients uncontrolled or intolerant. Since alternative therapies for the disease also have considerable drawbacks, the analyst reasoned that IMVT-1402 has potential as a novel, disease-modifying therapy. It reduces pathogenic IgG autoantibodies to target the disease's root cause, and positive proof-of-concept data from a first-generation anti-FcRn supports the therapy's efficacy. The analyst further reasoned that feedback from key opinion leaders highlights the significant need and demand for such targeted treatments, painting a positive picture for Immunovant, Inc. (NASDAQ:IMVT). Apart from IMVT-1402's dual effects in Graves' disease and thyroid eye disease, the company's ongoing trials further support the optimistic rating. Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn). While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
31-05-2025
- Business
- Business Insider
LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $9.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Rocket Pharmaceuticals also received a Buy from Bank of America Securities's Jason Zemansky in a report issued on May 28. However, yesterday, Evercore ISI downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) to a Hold. Based on Rocket Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $61.33 million. In comparison, last year the company had a GAAP net loss of $62.05 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year. Earlier this month, John Militello, the VP of Finance, Treasurer, Principal Accounting Officer of RCKT sold 357.00 shares for a total of $2,299.08.
Business Insider
31-05-2025
- Business
- Business Insider
Liquidia Technologies (LQDA) Receives a Buy from LifeSci Capital
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $41.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Liquidia Technologies also received a Buy from H.C. Wainwright's Andrew Fein in a report issued on May 29. However, on May 19, Oppenheimer downgraded Liquidia Technologies (NASDAQ: LQDA) to a Sell.
